stoxline Quote Chart Rank Option Currency Glossary
  
Atai Life Sciences N.V. (ATAI)
1.57  0.08 (5.37%)    07-23 16:00
Open: 1.5
High: 1.6
Volume: 457,239
  
Pre. Close: 1.49
Low: 1.49
Market Cap: 263(M)
Technical analysis
2024-07-23 4:50:32 PM
Short term     
Mid term     
Targets 6-month :  1.95 1-year :  2.27
Resists First :  1.66 Second :  1.95
Pivot price 1.44
Supports First :  1.41 Second :  1.25
MAs MA(5) :  1.52 MA(20) :  1.41
MA(100) :  1.75 MA(250) :  1.6
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  62.6 D(3) :  60.8
RSI RSI(14): 58
52-week High :  2.84 Low :  1.02
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ATAI ] has closed below upper band by 25.7%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.6 - 1.61 1.61 - 1.62
Low: 1.47 - 1.48 1.48 - 1.49
Close: 1.56 - 1.57 1.57 - 1.58
Company Description

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Headline News

Mon, 15 Jul 2024
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way? - Simply Wall St

Thu, 11 Jul 2024
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Wed, 03 Jul 2024
ATAI Life Sciences stock maintains 'Buy' from TD Cowen after Phase 1 study results - Investing.com

Wed, 26 Jun 2024
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - StockTitan

Wed, 12 Jun 2024
7 Best Psychedelic Stocks in 2024 | Investing - U.S News & World Report Money

Thu, 16 May 2024
atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe - Proactive Investors USA

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 167 (M)
Held by Insiders 1.2823e+008 (%)
Held by Institutions 10 (%)
Shares Short 6,900 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1411e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -41 %
Return on Assets (ttm) 314.7 %
Return on Equity (ttm) -26.1 %
Qtrly Rev. Growth 277000 %
Gross Profit (p.s.) 0
Sales Per Share -19.9
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -86 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.08
Price to Cash Flow 0.93
Stock Dividends
Dividend 0
Forward Dividend 8.32e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android